SENSE device: The SENSE Device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage and/or cerebral edema.
Study summary
The study population will consist of 3 mutually-exclusive sets of patients and subjects:
* TBI patients with intracranial bleeding
* TBI patients without intracranial bleeding
* Control subjects with normal brain health.
Research subjects ages 22 and older will be enrolled. All TBI patients must be monitored with the SENSE Device within 6 hours of a diagnostic head CT scan ordered by a treating clinician and within 24 hours of injury.
Eligibility
Sex
ALL
Min age
22 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
* • Male or female adults age 22 and older
* Patients with TBI who have a head CT scan obtained in the mobile stroke unit, emergency department, or hospital, ordered by a treating clinician OR control subjects with normal brain health.
* For patients with traumatic intracranial hemorrhage, blood is visible on ≥ 3 consecutive axial CT slices.
* Signed written informed consent by study subject or, if subject is unable, by subject's next of kin or legally authorized representative.
* Willingness and ability to comply with schedule for study procedures.
Exclusion Criteria:
* • Female patients who are pregnant or lactating.
* SENSE Device is unable to be placed within 6 hours of a standard of care head CT and within 24 hours of injury.
* Open skull fracture (closed skull fracture is not an exclusion).
* Metallic intracranial clip, coil, or device (such as metallic ICP monitor).
* Presence or history of any other condition or finding that, in the investigator's opinion, makes the patient unsuitable as a candidate for the SENSE Device monitoring or study participation or may confound the outcome of the study.
* Planned placement of an intraventricular catheter prior to study enrollment.
* Planned intracranial surgery prior to study enrollment.
* Current participation in a medical or surgical interventional clinical trial.
* Use of continuous EEG monitoring at the time of enrollment.
* Clinical uncertainty about the presence or absence of hemorrhage on the enrolling head CT.
* Control subjects with normal brain health will have no known history of seizure, stroke, brain tumor, TBI requiring emergency room evaluation, concussion within the previous 6 months, hydrocephalus, intracranial vascular malformation, other structural brain disease, or intracranial surgery. Benign headache disorders (e.g. migraine headache, tension headache), and mild concussion \> 6 months prior to enrollment are not exclusions.
Primary outcome measure(s)
Primary Efficacy Endpoint — 12 months The SENSE output for each patient will be classified as showing intracranial hemorrhage or no intracranial hemorrhage for each study CT with corresponding SENSE data. The SENSE output will be compared with the gold standard (CT scan result) to determine the accuracy of the SENSE Device as classifying TBI patients with and without intracranial hemorrhage correctly.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.